Bristol Myers Squibbvs.Merck & Co.
BMY vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Merck & Co. is about 2.6× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (19.6 vs 34.1); year to date, Merck & Co. leads (+17.4% vs +6.7%).
Side by side
| BMY | MRK | |
|---|---|---|
| Market cap | $117B | $305B |
| Price | $57.58 | $123.54 |
| Today | −0.6% | −1.2% |
| Return YTD | +6.7% | +17.4% |
| Return 1Y | +18.7% | +47.0% |
| P/E | 19.6 | 34.1 |
| P/S | 2.4 | 4.6 |
| P/B | 5.8 | 6.7 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Full BMY profile →Merck & Co.MRK
American pharmaceutical group with strengths in oncology (Keytruda), vaccines and animal health.
Full MRK profile →More comparisons in Big pharma
See where BMY and MRK sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →